Prosecution Insights
Prosecution Insights
12 pending office actions • 11 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (42%) |
| No statute on record | 7 (58%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKE-SCHLESSEL, DAVID W | 1 | 66.5% | +32.1% |
| MOSS, NATALIE M | 1 | 31.2% | +17.2% |
| HASAN, KHALEDA B | 1 | 58.6% | +49.3% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.4% |
| CRAIGO, BAHAR ALAWI | 1 | 46.9% | +27.0% |
| NGUYEN, QUANG | 1 | 38.2% | +52.8% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.6% | +42.1% |
| AFREMOVA, VERA | 1 | 50.6% | +29.2% |
| JAVANMARD, SAHAR | 1 | 65.3% | +35.6% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.3% | +24.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18053160 | GENE THERAPY CONSTRUCTS AND METHODS OF USE | HASAN, KHALEDA B | 124d overdue |
| 17767803 | VARIANT IGF2 CONSTRUCTS | WEHBE, ANNE MARIE SABRINA | 86d overdue |
| 18222745 | Dosing Regimens For The Treatment Of Fabry Disease | MOSS, NATALIE M | 74d overdue |
| 17665969 | Methods for Treatment of Fabry Disease | JAVANMARD, SAHAR | 70d overdue |
| 17618277 | Methods Of Treating Fabry Disease In Patients Having Renal Impairment | WHITE, DAWANNA SHAR-DAY | 32d overdue |
| 17838820 | Use Of Migalastat For Treating Fabry Disease In Pregnant Patients | CRAIGO, BAHAR ALAWI | 10d overdue |
| 17640456 | Method For Capturing And Purification Of Biologics | AFREMOVA, VERA | 12d |
| 18276954 | Recombinant Human Acid Alpha-Glucosidase and Uses Thereof | BERKE-SCHLESSEL, DAVID W | 15d |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| 1651 | 1 |
| 1636 | 1 |
| 1656 | 1 |
| 1699 | 1 |
| 1631 | 1 |
| 1634 | 1 |
| 1622 | 1 |
| 1627 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18276954 | Recombinant Human Acid Alpha-Glucosidase and Uses Thereof | BERKE-SCHLESSEL, DAVID W | 1651 | Other | Final Rejection | 15d | Pending | Aug 11, 2023 |
| 18222745 | Dosing Regimens For The Treatment Of Fabry Disease | MOSS, NATALIE M | 1653 | §103 | Final Rejection | 74d overdue | Pending | Jul 17, 2023 |
| 18053160 | GENE THERAPY CONSTRUCTS AND METHODS OF USE | HASAN, KHALEDA B | 1636 | Other | Non-Final OA | 124d overdue | Pending | Nov 07, 2022 |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | STEADMAN, DAVID J | 1656 | §103 | Non-Final OA | 19d | Pending | Jun 13, 2022 |
| 17838820 | Use Of Migalastat For Treating Fabry Disease In Pregnant Patients | CRAIGO, BAHAR ALAWI | 1699 | §103 | Final Rejection | 10d overdue | Pending | Jun 13, 2022 |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 1631 | §103 | Non-Final OA | 27d | Pending | Apr 29, 2022 |
| 17767803 | VARIANT IGF2 CONSTRUCTS | WEHBE, ANNE MARIE SABRINA | 1634 | Other | Non-Final OA | 86d overdue | Pending | Apr 08, 2022 |
| 17640456 | Method For Capturing And Purification Of Biologics | AFREMOVA, VERA | 1653 | §103 | Final Rejection | 12d | Pending | Mar 04, 2022 |
| 17665969 | Methods for Treatment of Fabry Disease | JAVANMARD, SAHAR | 1622 | Other | Final Rejection | 70d overdue | Pending | Feb 07, 2022 |
| 17618277 | Methods Of Treating Fabry Disease In Patients Having Renal Impairment | WHITE, DAWANNA SHAR-DAY | 1627 | Other | Final Rejection | 32d overdue | Pending | Dec 10, 2021 |
| 17606414 | COMPOSITIONS USEFUL FOR TREATMENT OF POMPE DISEASE | ROGERS, ERIC JASON | 1638 | Other | Non-Final OA | 113d overdue | Pending | Oct 25, 2021 |
| 16967824 | Treatment Of Patients With Classic Fabry Disease | CHONG, YONG SOO | 1623 | Other | Final Rejection | 32d overdue | Pending | Aug 06, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial